{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:57:02Z","timestamp":1791233822344,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":297,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.prdoa.2023.100227","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T01:15:48Z","timestamp":1698801348000},"page":"100227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson\u2019s disease"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6954-591X","authenticated-orcid":false,"given":"Noriyuki","family":"Miyaue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2023.100227_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000215875","article-title":"Levodopa: past, present, and future","volume":"62","author":"Hauser","year":"2009","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.prdoa.2023.100227_b0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/ern.13.47","article-title":"Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease","volume":"13","author":"Wright","year":"2013","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.prdoa.2023.100227_b0015","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002826-198712000-00004","article-title":"Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients","volume":"10","author":"Baruzzi","year":"1987","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.prdoa.2023.100227_b0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fnagi.2017.00206","article-title":"Protein-restricted diets for ameliorating motor fluctuations in Parkinson's disease","volume":"9","author":"Wang","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.prdoa.2023.100227_b0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mdc3.12908","article-title":"Impact of residual drug in the pharynx on the delayed-on phenomenon in Parkinson's disease patients","volume":"7","author":"Fukae","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.prdoa.2023.100227_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116855","article-title":"Abnormal upper gastrointestinal structures underlying levodopa malabsorption","volume":"414","author":"Miyaue","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.prdoa.2023.100227_b0035","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1212\/01.wnl.0000221672.01272.ba","article-title":"Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations","volume":"66","author":"Pierantozzi","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2023.100227_b0040","doi-asserted-by":"crossref","first-page":"e2443","DOI":"10.1212\/WNL.0000000000201204","article-title":"Association between microbial tyrosine decarboxylase gene and levodopa responsiveness in patients with Parkinson disease","volume":"99","author":"Zhang","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2023.100227_b0045","doi-asserted-by":"crossref","first-page":"e2672","DOI":"10.1002\/brb3.2672","article-title":"Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide","volume":"12","author":"Miyaue","year":"2022","journal-title":"Brain Behav"},{"key":"10.1016\/j.prdoa.2023.100227_b0050","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00228-018-2568-4","article-title":"Effects of magnesium oxide on pharmacokinetics of L-dopa\/carbidopa and assessment of pharmacodynamic changes by a model-based simulation","volume":"75","author":"Kashihara","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.prdoa.2023.100227_b0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3999\/jscpt.54.1_3","article-title":"Differing Patterns of Diurnal Variation and Impact of Antacids on Levodopa Pharmacokinetics in Patients with Parkinson's Disease","volume":"54","author":"Nagai","year":"2023","journal-title":"Jpn. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.prdoa.2023.100227_b0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2020.05.020","article-title":"Female, aging, difference formulations of DCI, or lower body weight increases AUC(4hr) of levodopa in patients with Parkinson's disease","volume":"76","author":"Nishikawa","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2023.100227_b0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.prdoa.2023.100227_b0070","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2023.100227_b0075","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.3233\/JPD-223374","article-title":"Sex Is the main determinant of levodopa clinical pharmacokinetics: evidence from a large series of levodopa therapeutic monitoring","volume":"12","author":"Contin","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.prdoa.2023.100227_b0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.parkreldis.2010.11.002","article-title":"Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease","volume":"17","author":"Nagayama","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2023.100227_b0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/00365520410005911","article-title":"Gastric acid secretion of normal Japanese subjects in relation to Helicobacter pylori infection, aging, and gender","volume":"39","author":"Iijima","year":"2004","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.prdoa.2023.100227_b0090","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.prdoa.2023.100227_b0095","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.parkreldis.2014.09.026","article-title":"Risk of Parkinson's disease following severe constipation: a nationwide population-based cohort study","volume":"20","author":"Lin","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2023.100227_b0100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"14","author":"Fasano","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.prdoa.2023.100227_b0105","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/mds.20942","article-title":"Excess burden of constipation in Parkinson's disease: a pilot study","volume":"21","author":"Kaye","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2023.100227_b0110","article-title":"Increasing the solubility of levodopa and carbidopa using ionization approach","volume":"44","author":"Krisai","year":"2020","journal-title":"Thai J. Pharmaceut. Sci."},{"key":"10.1016\/j.prdoa.2023.100227_b0115","first-page":"264","article-title":"Gastric acid secretion and absorption of levodopa in patients with Parkinson's disease\u2013the effect of supplement therapy to gastric acid","volume":"34","author":"Yazawa","year":"1994","journal-title":"Rinsho Shinkeigaku."},{"key":"10.1016\/j.prdoa.2023.100227_b0120","first-page":"68","article-title":"Pharmacokinetics of levodopa\/benserazide versus levodopa\/carbidopa in healthy subjects and patients with Parkinson's disease, Neurol","volume":"3","author":"Iwaki","year":"2015","journal-title":"Clin. Neurosci."},{"key":"10.1016\/j.prdoa.2023.100227_b0125","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the Motor Examination part of MDS-UPDRS","volume":"21","author":"Horv\u00e1th","year":"2015","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112523000452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112523000452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T11:15:38Z","timestamp":1736507738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112523000452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":25,"alternative-id":["S2590112523000452"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2023.100227","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2023.100227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100227"}}